James Lillard to Antineoplastic Agents
This is a "connection" page, showing publications James Lillard has written about Antineoplastic Agents.
Connection Strength
0.340
-
Singh SK, Singh S, Lillard JW, Singh R. Drug delivery approaches for breast cancer. Int J Nanomedicine. 2017; 12:6205-6218.
Score: 0.092
-
Huang MB, Gonzalez RR, Lillard J, Bond VC. Secretion modification region-derived peptide blocks exosome release and mediates cell cycle arrest in breast cancer cells. Oncotarget. 2017 Feb 14; 8(7):11302-11315.
Score: 0.089
-
Johnson-Holiday C, Singh R, Johnson EL, Grizzle WE, Lillard JW, Singh S. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World J Surg Oncol. 2011 May 03; 9:46.
Score: 0.060
-
Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009 Jun; 86(3):215-23.
Score: 0.051
-
Kapur N, Mir H, Sonpavde GP, Jain S, Bae S, Lillard JW, Singh S. Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel. Cancer Lett. 2019 07 10; 454:1-13.
Score: 0.026
-
Singh SK, Banerjee S, Acosta EP, Lillard JW, Singh R. Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/ p21WAF1/CIP1 and p27KIP1 pathway. Oncotarget. 2017 Mar 07; 8(10):17216-17228.
Score: 0.022